Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co. KGaA    FRE   DE0005785604


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius : Medical Care stays on course for growth – Annual General Meeting approves 22nd straight dividend increase

share with twitter share with LinkedIn share with facebook
share via e-mail
05/16/2019 | 09:28am EDT

Fresenius Medical Care, the world's largest provider of dialysis products and services, is investing in further growth. At the Annual General Meeting in Frankfurt today, CEO Rice Powell explained the company's growth strategy: 'We will be investing to the benefit of our patients - in innovation, efficiency and areas of growth. We have already taken important steps in this direction: We want to continuously improve dialysis care in a number of ways. Because we are vertically integrated, we are ideally placed to develop innovations for a range of applications, from diagnosis to treatment.'

A large shareholder majority of 89.78 percent approved the company's 22nd consecutive dividend increase. The dividend will be raised from €1.06 to €1.17, an increase of 10 percent.

With large majorities, the Annual General Meeting elected two new members as shareholder representatives to the Supervisory Board: Dr. Dorothea Wenzel, Executive Vice President and Head of the Global Business Unit Surface Solutions at Merck KGaA, and Professor Dr. Gregor Zünd, Chief Executive Officer of the University Hospital of Zurich. The two by-elections were necessitated by the departures of Dr. Gerd Krick and Deborah Doyle McWhinney from the Supervisory Board last year.

Shareholder majorities of 56.81 and 52.32 percent, respectively, approved the actions of the General Partner and the Supervisory Board in 2018.

At the Annual General Meeting, 76.68 percent of the subscribed capital was represented.

The next Annual General Meeting is scheduled for May 19, 2020.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.


Fresenius SE & Co. KGaA published this content on 16 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 16 May 2019 13:27:04 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on FRESENIUS SE & CO. KGAA
10/16FRESENIUS : celebrates expansion of Bad Homburg headquarters
10/08Deutsche Bank's chairman best paid among German blue chips in 2018
10/07FRESENIUS : Kabi launches Fulvestrant in prefilled syringes in the U.S.
09/30FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the Germa..
09/16FRESENIUS : 2020 DRG inflator for German hospitals set at 3.66%
09/15Fresenius drops possible sale of blood transfusion unit - spokesman
09/13FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
09/11FRESENIUS : Helios launches digital portal for patients
09/09FRESENIUS : Medical Care's publishes annual medical report
09/06FRESENIUS : Medical Care builds new laboratory in Mississippi
More news
Financials (EUR)
Sales 2019 35 389 M
EBIT 2019 4 676 M
Net income 2019 1 846 M
Debt 2019 20 659 M
Yield 2019 1,85%
P/E ratio 2019 13,1x
P/E ratio 2020 12,0x
EV / Sales2019 1,27x
EV / Sales2020 1,11x
Capitalization 24 163 M
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 56,25  €
Last Close Price 43,37  €
Spread / Highest target 72,5%
Spread / Average Target 29,7%
Spread / Lowest Target -25,2%
EPS Revisions
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors